Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

There is significant variability in the efficacy and safety of oral P2Y12 inhibitors, which are
used to prevent ischemic outcomes in common diseases such as coronary and peripheral …

Aim: To understand how attitudes toward pharmacogenomic (PGx) testing among
healthcare providers varies by specialty. Methods: Providers reported comfort ordering PGx …

Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and
aspirin remains the standard of care for all patients undergoing percutaneous coronary …

Cardiac aging, particularly cardiac cell senescence, is a natural process that occurs as we
age. Heart function gradually declines in old age, leading to continuous heart failure, even in …

Background The long-term prognostic implication of platelet reactivity after percutaneous
coronary intervention (PCI) is not clearly known. Objectives The impacts of platelet reactivity …

Oral P2Y12 inhibitors are commonly prescribed for cardiovascular disease and include
clopidogrel, prasugrel, and ticagrelor. Each of these drugs has its strengths and …

The Age, Body mass index, Chronic kidney disease, Diabetes mellitus, and CYP2C19
GENEtic variants (ABCD‐GENE) score was developed to identify patients at risk for …

Background Although there is a growing body of evidence that CYP2C19 genotyping can be
beneficial when considering treatment with clopidogrel after percutaneous coronary …

Abstract Background An ABCD-GENE (age, body mass index, chronic kidney disease,
diabetes, and CYP2C19 genetic variants) score≥ 10 predicts reduced clopidogrel …